For the second year running, Comdisco's annual survey of the average age of medical imaging equipment shows lengthening scanner life cycles in all modalities. The Rosemont, IL, equipment refurbisher and financing firm said the phenomenon was attributable
For the second year running, Comdisco's annual survey of the average age of medical imaging equipment shows lengthening scanner life cycles in all modalities. The Rosemont, IL, equipment refurbisher and financing firm said the phenomenon was attributable to the drop in purchasing of new capital equipment, which results in hospitals holding on to their equipment for longer periods.
MRI scanners were particularly hard hit. The average age of installed MRI systems was 4.5 years in 1995, up from 3.1 years in 1992. In addition, 70% of MRI scanners are over three years old, compared to 35% in 1992.
The average age of other modalities in 1995 versus 1992 was as follows:
Radiography/fluoroscopy equipment continues to be the most elderly modality, with the average R/F system in 1995 purchased 10.1 years ago, compared to an average age of 7.9 years in 1992. The survey indicates that 20% of R/F systems are over 15 years old.
Not surprisingly, hospitals suffering from new-scanner sticker shock are turning to refurbished equipment, Comdisco said. The company's shipments of reconditioned medical imaging equipment this year increased 17% to $28 million, and the firm is entering 1996 with a record order backlog.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.